Glaukos Corporation ranks seventh among the 13 most oversold healthcare stocks in 2025. The company specializes in ophthalmic pharmaceutical and surgical therapies, with innovative treatment platforms like the FDA-approved iDose sustained-release implant for glaucoma. Q2 net sales rose 30% to $124.1 million, driven by strong adoption of their products.

Glaukos Corporation (GKOS) reported robust growth in 2025, with Q2 net sales up 30% year-over-year to $124.1 million. U.S. glaucoma treatment sales reached $72.3 million in the quarter, leading the company to raise full-year guidance to $480-$486 million. Despite recent overselling, GKOS has maintained strong operational performance.

GKOS is advancing its pipeline with next-gen therapies like the iDose TREX implant and ongoing trials for iStent Infinite and PRESERFLO devices. The company’s Epioxa, a non-invasive epi-on corneal cross-linking therapy for keratoconus, received FDA acceptance for review with a PDUFA date of October 20, 2025.

While GKOS shows promise as an investment, some AI stocks may offer greater upside potential. For those interested in undervalued AI stocks benefiting from current trends, consider exploring opportunities in the market.

Read more at Yahoo Finance: Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa